

MINUTES
UTAH
CONTROLLED SUBSTANCES ADVISORY COMMITTEE
MEETING

September 9, 2013

Room 464, 4th Floor – 4:00 P.M.
Heber M. Wells Building
Salt Lake City, UT 84111

CONVENED: 4:06 p.m.

ADJOURNED: 5:30 p.m.

Bureau Manager:
Board Secretary:

Debra Hobbins, DNP, APRN
Shirlene Kimball

Division Staff:

Marvin Sims, Controlled Substance Database

Committee Members Present:

David N. Sundwall, MD, Chairperson
Deputy Commissioner Jeff Carr
Blaine Winters, APRN
Todd C. Grey, MD
Elizabeth Howell, MD
Darin M. Vercillo, MD
Scott W. Reed, AAG
Elizabeth Howell, MD
Jeffrey Paul Clark, MD
Jeffrey Wright, ND

Committee Members Excused:

Glen R Hanson, Ph.D, DDS
David Young, Pharm D
Kenneth Schaecher, MD

Guests:

Representative Ronda Menlove
Barbara Crouch, Pharm D, MSPH Utah Poison Control
Jennifer McNair, Bureau of Forensic Services
Brian Oliver, MD, Utah ACEP

TOPICS FOR DISCUSSION

DECISIONS AND RECOMMENDATIONS

ADMINISTRATIVE BUSINESS:
February 25, 2013 Minutes:

Dr. Clark made a motion to approve the February 25, 2013 minutes as written. Dr. Vercillo seconded the motion. All Board members voted in favor of the motion.

April 29, 2013 Minutes:

Dr. Clark made a motion to approve the April 29, 2013

minutes as written. Dr. Vercillo seconded the motion. All Board members voted in favor of the motion.

Dr. Sundwall:

Dr. Sundwall welcomed Representative Ronda Menlove. He explained the duties of the Committee which include: serving as a consultative and advisory body to the Legislature regarding the designation of a substance as a controlled substance, the movement of a controlled substance from one schedule to another, and the removal of a controlled substance from a schedule.

Dr. Sundwall indicated that the Health and Human Services Interim Committee approved the recommendations from the 2012 annual report with the exception of allowing the Controlled Substances Advisory Committee to temporarily approve a substance to be added to the Controlled Substance list during the portion of the year remaining until the Legislative session.

Jennifer McNair report:

Ms. McNair provided the Committee with a list of new analogs. This list included:

- a. **MAM-2201**; (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone
- b. **PB-22**; 1-pentyl-1*H*-indole-3-carboxylic acid 8-quinolinyl ester
- c. **5-fluoro-PB-22**; 1-(5-fluoropentyl)-1*H*-indole-3-carboxylic acid 8-quinolinyl ester
- d. **AB-PINACA**; N-[1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide
- e. **AB-FUBINACA**; N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
- f. **25H-NBOMe**; 2-(2,5-dimethoxyphenyl)-*N*-[(2-methoxyphenyl)methyl]ethanamine.

Ms. McNair stated she feels that there has been a slight decrease in the use of some of the substances that have been added to the Controlled Substances list. Mr. Reed questioned Ms. McNair on what type of reduction has been seen. Ms. McNair stated there appears to be a little less bath salts and spice; however, this is just an observation and she will provide a more detailed report to the Committee in the future. Dr. Vercillo questioned if adding these analogs have driven people from spice back to cocaine. Dr. Howell indicated if an individual is

addicted, they are addicted to whatever is available. Ms. McNair also indicated that authorities in Boston have reported a new drug known as "Molly." This drug has been attributed to a number of deaths due to the impurities and substances used to make the drug.

Dr. Crouch, Utah Poison Control, indicated they have seen a trend in the use of "food coloring," the street name for liquid spice/K2 used in e-cigarettes. Dr. Crouch also reported they are seeing "Jack 3d", which contains dimethylamylamine, a weight loss drug from the 1940s that has emerged in sports supplements.

Dr. Oliver, emergency room physician, indicated that it appears the trend for drug use is slightly down, especially for prescription drugs. Dr. Grey reported that the use of prescription opioids is going back up. He indicated the use of methadone has dropped off slightly, but the use of oxycodone has risen.

Tramadol Report:

Dr. Crouch reported it is very difficult to pull out much information on Tramadol at this point.

Dr. Hobbins reported since Tramadol was scheduled in May, there have been no negative comments regarding having it scheduled.

Dan Stapleton, a pharmacist from the Substance Misuse and Abuse Reduction Team (SMART) reported by telephone. He indicated there have been positive comments regarding the scheduling of Tramadol, both from prescribers and from patients. He indicated there was one individual who received 4000 Tramadol tablets within a three-month period and the authorities were contacted.

Mr. Sims indicated Tramadol was reported to the Controlled Substance Database prior to May 14, 2013, but it was not reported on a regular base. He stated that prior to May 2013 there were 15273 Tramadol prescriptions reported. Since the law went into effect, 104,352 additional prescriptions have been entered with a total of 5858 prescribers. He indicated these are all outpatient prescriptions. Mr. Sims indicated the database was not expecting that many Tramadol prescriptions even though it is a low number of prescriptions, with only 1% of prescribers prescribing Tramadol. Dr. Howell stated

that some of the prescriptions may be written by veterinarians for use with animals. She indicated that Tramadol is a medication that can be used in animals and could possibly increase the total number of Tramadol prescriptions. Dr. Howell questioned if there is a plan to send out a letter informing prescribers “this is what you are prescribing.” Mr. Sims stated there were problems with the letters and the Division ceased sending them out. Dr. Sundwall suggested sending a letter indicating all prescribers are receiving this letter, and this is where you stand in terms of controlled substance prescriptions. Dr. Vercillo stated whenever he writes a prescription for Ultram, he pats himself on the back for writing for an alternative to an opioid because he feels Ultram is less addictive. He indicated the Division needs to be careful about the message that is being sent. He suggested that instead of saying, “do you realize how much you are prescribing”, ask if they feel they are prescribing a medication with a less addictive profile. Dr. Howell stated Tramadol is less addictive, but still addictive and not everyone knows that it is addictive. Dr. Clark suggest saying “here is your over all use of a potentially addictive drug.” There is a lower chance of addiction, but the potential is still there.

Committee members thanked Mr. Sims for the information.

Update from:

Law enforcement: Deputy Carr reported that all major law enforcement agencies signed a letter to the Department of Justice regarding the DOJ’s stance that they will not prosecute those states that have legalized marijuana. He indicated it does not appear that there has been an increase in trafficking in Utah since Colorado and Washington legalized marijuana.

Ms. McNair indicated she would be attending the National Alliance for Model State Drug Laws to participate in the drafting of model synthetic substances/controlled substance analogue law. She indicated the Alliance serves as a resource for governors, state legislators, and others striving to develop comprehensive and effective state drug and alcohol laws, policies, and regulations.

Medical Examiner: Dr. Grey indicated that there has been an uptake in number of drug deaths, non-suicidal,

with Tramadol mentions. Tramadol is not the cause, but is mentioned in the reports. He indicated it is discouraging to see the number going back up, in what appears to be a nationwide trend.

National trends and policies:

Dr. Sundwall reported it appears there may be a bill to legalize marijuana for medical use in Utah. He also indicated there may be a bill regarding e-cigarettes.

Open and Public Meetings Act Training:

Dr. Hobbins reviewed with Committee members the Open and Public Meetings Act requirements. Dr. Hobbins indicated that a recent example of Committee dialogue was the email exchange of information on e-cigarettes. She cautioned Committee members that some issues should be placed on the agenda for discussion and for public input.

Annual Report to the Health and Human Services Interim Committee:

Dr. Howell made the motion to add to the annual report the substances discussed by Ms. McNair. Dr. Vercillo seconded the motion. Dr. Sundwall suggested adding to the report Ms. McNair's invitation by the National Alliance for Model State Drug Laws to participate in the drafting of model synthetic substances/controlled substance analogue law. He also indicated he would like to add that the Committee will be reviewing the collection of data on Tramadol regarding the extent of the use and abuse of this prescription medication. All Board members voted in favor of the motion with Dr. Sundwall's suggested additions.

Scheduling of next meeting:

Dr. Howell indicated future agendas should include the discussion regarding medical marijuana and the discussion of e-cigarettes and whether the e-cigarette topic is within the Committee's scope.

Note: These minutes are not intended to be a verbatim transcript but are intended to record the significant features of the business conducted in this meeting. Discussed items are not necessarily shown in the chronological order they occurred.

11/12/2013
Date Approved

(ss) David N. Sundwall
David N. Sundwall, Chairperson, Controlled
Substances Advisory Committee

11/12/2013
Date Approved

(ss) Debra Hobbins
Debra Hobbins, Bureau Manager, Division of
Occupational & Professional Licensing